404 related articles for article (PubMed ID: 10081870)
1. Ultrasensitive detection of prostate specific antigen in the followup of 422 patients after radical prostatectomy.
Haese A; Huland E; Graefen M; Hammerer P; Noldus J; Huland H
J Urol; 1999 Apr; 161(4):1206-11. PubMed ID: 10081870
[TBL] [Abstract][Full Text] [Related]
2. Supersensitive PSA-analysis after radical prostatectomy: a powerful tool to reduce the time gap between surgery and evidence of biochemical failure.
Haese A; Huland E; Graefen M; Huland H
Anticancer Res; 1999; 19(4A):2641-4. PubMed ID: 10470210
[TBL] [Abstract][Full Text] [Related]
3. Detection of prostate cancer relapse with prostate specific antigen monitoring at levels of 0.001 to 0.1 microG./L.
Yu H; Diamandis EP; Wong PY; Nam R; Trachtenberg J
J Urol; 1997 Mar; 157(3):913-8. PubMed ID: 9072598
[TBL] [Abstract][Full Text] [Related]
4. Ultrasensitive serum prostate specific antigen nadir accurately predicts the risk of early relapse after radical prostatectomy.
Shen S; Lepor H; Yaffee R; Taneja SS
J Urol; 2005 Mar; 173(3):777-80. PubMed ID: 15711268
[TBL] [Abstract][Full Text] [Related]
5. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
[TBL] [Abstract][Full Text] [Related]
6. Use of serum concentration techniques to enhance early detection of recurrent prostate cancer after radical prostatectomy.
Pruthi RS; Haese A; Huland E; Stamey TA
Urology; 1997 Mar; 49(3):404-10. PubMed ID: 9123706
[TBL] [Abstract][Full Text] [Related]
7. Lack of association of prostate carcinoma nuclear grading with prostate specific antigen recurrence after radical prostatectomy.
Zhou M; Hayasaka S; Taylor JM; Shah R; Proverbs-Singh T; Manley S; Rubin MA
J Urol; 2001 Dec; 166(6):2193-7. PubMed ID: 11696734
[TBL] [Abstract][Full Text] [Related]
8. Preoperative reverse transcriptase polymerase chain reaction for prostate specific antigen predicts treatment failure following radical prostatectomy.
Olsson CA; de Vries GM; Raffo AJ; Benson MC; O'Toole K; Cao Y; Buttyan RE; Katz AE
J Urol; 1996 May; 155(5):1557-62. PubMed ID: 8627821
[TBL] [Abstract][Full Text] [Related]
9. An analysis of 148 consecutive transition zone cancers: clinical and histological characteristics.
Noguchi M; Stamey TA; Neal JE; Yemoto CE
J Urol; 2000 Jun; 163(6):1751-5. PubMed ID: 10799175
[TBL] [Abstract][Full Text] [Related]
10. Is preoperative serum prostate-specific antigen level significantly related to clinical recurrence after radical retropubic prostatectomy for localized prostate cancer?
Haukaas SA; Halvorsen OJ; Daehlin L; Hostmark J; Akslen LA
BJU Int; 2006 Jan; 97(1):51-5. PubMed ID: 16336328
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of ultrasensitive prostate-specific antigen assay for early detection of biochemical failure after radical prostatectomy.
Nakamura M; Hasumi H; Miyoshi Y; Sugiura S; Fujinami K; Yao M; Kubota Y; Uemura H
Int J Urol; 2005 Dec; 12(12):1050-4. PubMed ID: 16409609
[TBL] [Abstract][Full Text] [Related]
12. Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy.
Blute ML; Bostwick DG; Bergstralh EJ; Slezak JM; Martin SK; Amling CL; Zincke H
Urology; 1997 Nov; 50(5):733-9. PubMed ID: 9372884
[TBL] [Abstract][Full Text] [Related]
13. Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
Amling CL; Blute ML; Bergstralh EJ; Seay TM; Slezak J; Zincke H
J Urol; 2000 Jul; 164(1):101-5. PubMed ID: 10840432
[TBL] [Abstract][Full Text] [Related]
14. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
[TBL] [Abstract][Full Text] [Related]
15. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
[TBL] [Abstract][Full Text] [Related]
16. Prostate specific antigen recurrence rates are low after radical retropubic prostatectomy and positive margins.
Simon MA; Kim S; Soloway MS
J Urol; 2006 Jan; 175(1):140-4; discussion 144-5. PubMed ID: 16406892
[TBL] [Abstract][Full Text] [Related]
17. Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer.
Pruthi RS; Johnstone I; Tu IP; Stamey TA
Urology; 1997 May; 49(5):737-42. PubMed ID: 9145980
[TBL] [Abstract][Full Text] [Related]
18. Accuracy of predicting long-term prostate specific antigen outcome based on early prostate specific antigen recurrence results after radical prostatectomy.
Soergel TM; Koch MO; Foster RS; Bihrle R; Wahle G; Gardner T; Jung SH
J Urol; 2001 Dec; 166(6):2198-201. PubMed ID: 11696735
[TBL] [Abstract][Full Text] [Related]
19. Preoperative serum prostate specific antigen does not reflect biochemical failure rates after radical prostatectomy in men with large volume cancers.
Noguchi M; Stamey TA; McNeal JE; Yemoto CM
J Urol; 2000 Nov; 164(5):1596-600. PubMed ID: 11025712
[TBL] [Abstract][Full Text] [Related]
20. Percent free prostate specific antigen is not an independent predictor of organ confinement or prostate specific antigen recurrence in unscreened patients with localized prostate cancer treated with radical prostatectomy.
Graefen M; Karakiewicz PI; Cagiannos I; Hammerer PG; Haese A; Palisaar J; Huland E; Scardino PT; Kattan MW; Huland H
J Urol; 2002 Mar; 167(3):1306-9. PubMed ID: 11832719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
